Patents by Inventor John Löfblom
John Löfblom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101605Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for CD69 and provides a CD69-binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QK X21AFKX25X26LKD. The present disclosure also relates to the use of such a CD69-binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.Type: ApplicationFiled: December 21, 2021Publication date: March 28, 2024Inventors: John LÖFBLOM, Stefan STÅHL, Jonas PERSSON, Olof ERIKSSON, Olov KORSGREN
-
Publication number: 20210355180Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9A X11QLCAX16IX18X19X20 ED (SEQ ID NO:632). The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.Type: ApplicationFiled: July 22, 2021Publication date: November 18, 2021Inventors: Stefan Ståhl, John Löfblom, Hanna Lindberg, Torleif Härd
-
Patent number: 11098096Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9A X11QLCAX16IX18X19X20 ED (SEQ ID NO:632). The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.Type: GrantFiled: December 16, 2019Date of Patent: August 24, 2021Assignee: AMYLONIX ABInventors: Stefan Ståhl, John Löfblom, Hanna Lindberg, Torleif Härd
-
Publication number: 20200199197Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29 (SEQ ID NO:1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: January 15, 2020Publication date: June 25, 2020Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20200172588Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9A X11QLCAX16IX18X19X20 ED (SEQ ID NO:632). The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.Type: ApplicationFiled: December 16, 2019Publication date: June 4, 2020Inventors: Stefan Ståhl, John Löfblom, Hanna Lindberg, Torleif Härd
-
Patent number: 10562955Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: December 14, 2017Date of Patent: February 18, 2020Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20190284241Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: April 8, 2019Publication date: September 19, 2019Inventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Patent number: 10323066Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: September 17, 2015Date of Patent: June 18, 2019Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Patent number: 10208128Abstract: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.Type: GrantFiled: October 27, 2010Date of Patent: February 19, 2019Assignee: AFFIBODY ABInventors: Fredrik Frejd, Elin Gunneriusson, Nina Kronqvist, John Löfblom, Stefan Ståhl
-
Publication number: 20180118807Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: December 14, 2017Publication date: May 3, 2018Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20180057551Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9AX11QLCAX16IX18X19X20 ED. The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.Type: ApplicationFiled: February 22, 2016Publication date: March 1, 2018Inventors: Stefan Ståhl, John Löfblom, Hanna Lindberg, Torleif Härd
-
Publication number: 20170260238Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein said first and second monomer unit search comprises an FcRn binding motif. Said FcRn binding dimer binds FcRn with higher capacity compared to said first monomer unit or second monomer unit alone. The present disclosure also relates to the use of said FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: September 17, 2015Publication date: September 14, 2017Applicant: Affibody ABInventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Patent number: 9745350Abstract: The present disclosure relates to polypeptides which bind to human epidermal growth factor receptor 3 (HER3) and to use of such polypeptides in imaging and therapy. The disclosure provides an HER3 binding polypeptide comprising a HER3 binding motif, which motif consists of the amino acid sequence EKYX4AYX7EIW X11LPNLTX17X18QX20 AAFIGX26 LX28D (SEQ ID NO:110).Type: GrantFiled: October 3, 2013Date of Patent: August 29, 2017Assignee: AFFIBODY ABInventors: Magdalena Malm, John Löfblom, Stefan Ståhl
-
Publication number: 20160031967Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: March 17, 2014Publication date: February 4, 2016Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20150252079Abstract: The present disclosure relates to polypeptides which bind to human epidermal growth factor receptor 3 (HER3) and to use of such polypeptides in imaging and therapy.Type: ApplicationFiled: October 3, 2013Publication date: September 10, 2015Inventors: Magdalena Malm, John Löfblom, Stefan Ståhl
-
Publication number: 20120270801Abstract: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an N amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.Type: ApplicationFiled: October 27, 2010Publication date: October 25, 2012Applicant: AFFIBODY ABInventors: Fredrik Frejd, Elin Gunneriusson, Nina Kronqvist, John Löfblom, Stefan Ståhl